RALLYYYYYYYYYYYYYYY NDA filings / FDA approval(s) / Important Phase 2 results and the launch of the Cannabis Products A LOT OF BIG NEWS WILL COME DURING 2019 IntelGenx, Tilray working to launch cannabis-infused VersaFilm in late-2019 http://www.biotuesdays.com/briefs/2...aunch-cannabis-infused-versafilm-in-late-2019
GREAT buying opportunity here ....Price 0.35 -Market Cap $33 M--FDA DECISION for Migraine drug & Launch of Cannabis Products both expected during this Quarter !!!! Stock could run to $1++ ahead of the FDA decision in March .GL Cannabis-Infused VersaFilm® Remains on Track for Commercial Launch in Q1-2020 IntelGenx Continues to Make Preparations Ahead of RIZAPORT® PDUFA Goal Date of March 26, 2020
This is indeed a very good company with lots of upside potential imo. The current levels are a great opportunity to buy at low levels. There are only about 7 weeks left until the FDA decission on RIZAPORT. Plus they will launch their Cannabis film with Tilray. Below is a link to a Webcast of the company. December 10, 2019 12:30 PM EST BioTuesdays Pre-JPM Virtual Conference View the live Webcast
IntelGenx Completes C$8.2 Million Equity Offering February 11, 2020 10:14 ET | Source: IntelGenx Technologies Corp. https://www.globenewswire.com/news-...-Completes-C-8-2-Million-Equity-Offering.html IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 16,317,000 units (the “Units”) at a price of C$0.50 per Unit (the “Offering Price”) for gross proceeds of C$8,158,500.
Two major events upcoming, first the launch of their Cannabis film with Tilray in Q1, and the FDA decission on RIZAPORT end of March. If all plays out Intelgenx is a multibagger imo...
Nice gain today. Looking for more next week. This is only the beginning in anticipation of the FDA decision on Rizaport.
The Fascinating Story of IntelGenx Technologies Corp. (OTCMKTS: IGXT) By Dave Young on February 11, 2020 https://microcapdaily.com/the-fascinating-story-of-intelgenx-technologies-corp-otcmkts-igxt/124954/
I am confident that IntelGenx has a good chance of getting Rizaport approved this time around. The next few weeks will be interesting for sure. The FDA has assigned a Prescription Drug User Fee Act goal date for completion of the review of the RIZAPORT® NDA of March 26, 2020. Fingers crossed… IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA April 02, 2019 http://www.intelgenx.com/investors/...Letter-from-FDA-for-RIZAPORT-NDA/default.aspx The issues cited in the CRL relate to the Chemistry, Manufacturing and Controls section of the application. The Agency requested additional information, but no new bioequivalence study. "We believe the recommendations stated in the CRL are manageable and we remain committed to working closely with the FDA to make this innovative new oral film product available to people suffering from migraines,” said Horst G. Zerbe, President and CEO of IntelGenx.
This is a multibagger for sure if Rizaport gets approved end of March. IntelGenx: Oral films are drug development’s patent trick By Sophie Bullimore 16-Jan-2020 https://www.manufacturingchemist.co...lms_are_drug_developments_patent_trick/161519 Exploiting improvements in bioavailability, the Canadian company has developed unique oral film technology to help drugmakers secure exclusivity and financial returns
Looking at the general stock market my portfolio could definitely need a big winner. We are less than 4 weeks away from the FDA Rizaport PDUFA Goal Date of March 26, 2020. Fingers crossed...
"We are the king of the kingdom" (at 2:30 min) That's a good one 2 August 2019 IntelGenx Technologies Corp. | Pharmaceutical Insights Andre Godin, President & CEO of IntelGenx Technologies Corp. (TSX.V: IGX), interviewed by Jim Gordon at the 2019 inaugural TSX Venture 50 Capital Conference in Kelowna.
Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates BenzingaMarch 2, 2020 https://finance.yahoo.com/news/attention-biotech-investors-mark-calendar-214606172.html Can IntelGenx's Migraine Drug Clear FDA Hurdle After 7-Year Wait? Company: IntelGenx Technologies Corp. (OTC: IGXT) Type of Application: NDA Candidate: Rizaport VersaFilm Indication: acute migraines Date: March 26 Intelgenx is knocking the FDA door for its migraine drug for the fourth time following three prior rejections. The company's initial regulatory application was filed in June 2013. Rizaport is an oral soluble film formulation of rizatriptan benzoate, the active drug in Maxalt.
Moving up today. This should continue imo in anticipation of the FDA decision which is only 3 weeks away.
IntelGenx is one of the best stocks to own during such misery going on at the stock markets. IGXT has several near term milestones, has a low valuation is well financed untill year end and likely to be profitable soon if Rizaport gets approved and the cannabis film with Tilray gets launched early next quarter. The odds for approval of Rizaport this time is very high in my opinion with their new manufacturing facility.
We are 10 days away from the FDA Rizaport PDUFA Goal Date of March 26, 2020. I could definitely need a big winner in my portfolio...
I hope next week we will see a rise of the stock price in anticipation of FDA Rizaport PDUFA Goal Date of March 26, 2020. Fingers crossed for a positive FDA decision next week. Multibagger potential if all works out...
I am not aware that the FDA pushed back the date due to the virus. To my knowledge the FDA Rizaport PDUFA Goal Date of March 26, 2020 is still valid. What the FDA did decide recently is to halt inspections of all foreign drug manufacturer. This does not apply to IntelGenX. https://www.fiercepharma.com/manufa...pections-may-delay-some-new-product-approvals Mar 11, 2020 The FDA has decided that the risk of inspectors crossing paths with COVID-19 is greater than the risk to consumers of drugmakers failing to meet FDA standards and putting poor quality drugs on the market. The agency has decided to halt inspections of all foreign drug manufacturers after earlier putting inspections in China on hold. The FDA Tuesday said it will consider “mission critical” inspections on a case-by-case basis but otherwise is postponing foreign inspections in April. Instead, it will rely on help from regulators in other countries, testing products at the border for safety and wielding authority to deny entry to drugs considered defective or unsafe.
